What pharmacists need to know about the women's health initiative estrogen plus progestin trial.
Saseen
Joseph J
JJ
School of Pharmacy, Department of Family Medicine, University of Colorado Health Sciences Center, Denver, CO, USA. joseph.saseen@uchsc.edu
Hansen
Laura B
LB
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000139:chemically induced; D003327:Coronary Disease / Q000139:chemically induced / Q000401:mortality; D023381:Endpoint Determination; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D004966:Estrogens, Conjugated (USP) / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D010595:Pharmacists; D017698:Postmenopause; D045167:Progesterone Congeners / Q000009:adverse effects* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D015203:Reproducibility of Results; D018570:Risk Assessment; D016896:Treatment Outcome
D004966:Estrogens, Conjugated (USP); D045167:Progesterone Congeners; D008525:Medroxyprogesterone